Navigation Links
BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
Date:2/13/2013

Administration granted BHR-100 an Orphan Drug designation also for treating moderate and severe TBI and placed the drug on Fast Track status designed to accelerate its potential approval.

BHR initiated the SyNAPSe trial in June 2010 with a total enrollment target of 1,180 severe TBI patients. The trial is now more than 75 percent enrolled.  Last month, the SyNAPSe trial's Independent Data and Safety Monitoring Board (DSMB) released its formal interim analysis, concluding no safety issues exist, there was no reason to stop the study for futility and the trial may continue towards its intended completion. Patient enrollment is set to complete in 2013.

About Traumatic Brain Injury (TBI)
TBI is a serious public health problem that affects millions of people worldwide. There are approximately 66,000 deaths attributed annually to TBI in Europe.[1] According to the World Health Organization, traumatic brain injury is the leading cause of death and disability in children and young adults worldwide and is involved in nearly half of all trauma deaths. Despite significant efforts and more than 75 clinical trials over the past 20 years, there is still no approved treatment for TBI.

About BHR Pharma
Founded in January 2008, BHR Pharma, LLC (www.bhr-pharma.com) is a pharmaceutical research and development company located near Washington, DC, USA.  BHR is committed to bringing to market specialty treatments that employ non-oral delivery systems, with an emphasis on unmet and underserved medical needs. The company is a wholly owned subsidiary of Besins Healthcare SA (www.besins-healthcare.com), which markets healthcare products in 93 countries.

[1] Socin et al. JAMA273:22 (1995).


'/>"/>
SOURCE BHR Pharma, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NEW YORK , June 18, 2013 JDRF ... ) are accelerating the development of new products that combine ... new collaboration announced today. This new, three-year commitment is an ... (T1D). Many patients with T1D not only take ... to be placed in the body for a number of ...
(Date:6/18/2013)... EMERYVILLE, Calif. , June 18, 2013 ... today from a Phase 2/3 clinical trial of ... statistically significant improvement in levodopa-induced dyskinesia (LID) as ... versus placebo in the Unified Dyskinesia Rating Scale ... amantadine intended for once-nightly administration that is being ...
(Date:6/17/2013)... ANGELES , June 17, 2013 Velplex, ... TopProdeals.com , a technology platform that connects buyers and ... into being an industry leader. Why? ... at TopProdeals™ are intimately familiar with the dental industry. ... healthcare community and have diligently worked to negotiate some ...
Breaking Medicine Technology:JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
... ALLENTOWN, Pa., Jan. 9, 2012    Lehigh Valley Technologies, ... of a recently completed inspection by the U.S. ... 2011, FDA completed an onsite inspection with no ... that there were no negative observations relating to ...
... 9, 2012 Uptake Medical ® today announced ... round. The round was led by Singapore-based Crescent Point ... Venture Partners, WRF Capital, Arboretum Ventures and Affinity Capital, ... will join the Uptake Medical board of directors. Moelis ...
Cached Medicine Technology:Uptake Medical Announces Successful Completion of Series C Financing 2
(Date:6/18/2013)... New York (PRWEB) June 18, 2013 As ... both state and federal court, a new report has revealed ... than 70,000 U.S. Food & Drug Administration (FDA) adverse event ... to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena users have ... while more than 1,300 have reportedly experienced uterine perforations due ...
(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...
(Date:6/18/2013)... Lesbian, Gay, Bisexual and Transgender (LGBT) Pride ... sexual minority youth are still at greater ... according to the Suicide Prevention Resource Center. ... recently published recommendation to improve psychologists, treatment ... improve psychological functioning and reduce depression and ...
(Date:6/18/2013)... 18, 2013): With Medicare penalties on hospitals with ... in 2014, more hospitals are evaluating the most ... A new study appearing in the June issue ... of Surgeons finds that the American College ... NSQIP) led to more accurate data tracking than ...
(Date:6/18/2013)... June 18, 2013 Two weeks ago, eyes ... Philadelphia, Pennsylvania. As reported by CNN on ... building collapse, 13 injured," a building scheduled to be demolished ... shop, and six of those persons succumbed to their injuries. ... the country. , The situation should serve as a reminder ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Sexual minority youth need specialized treatment from therapists 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 3Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 4Health News:Ensuring The Safety of Pennsylvania Worksites 2Health News:Ensuring The Safety of Pennsylvania Worksites 3
... 28, 2010) Errors in diagnosis place a heavy ... and can be devastating for affected patients. Strengthening ... comprehensive and coordinated primary care could potentially address this ... from Baylor College of Medicine ( www.bcm.edu ) and ...
... Langone Medical Center has begun a clinical trial offering ... This novel, minimally invasive procedure uses a light-activated ... laser fibers in order to destroy prostate cancer cells. ... prostate cancer offers the potential to destroy the cancer ...
... rural hospitals may be quicker and more efficient at ... and are capable of providing a standard of surgical ... provide a comprehensive array of care services, according to ... the University of Louisville Department of Surgery. "The ...
... One of the human body,s most powerful defensive tools, ... toxins and viruses in the bloodstream from reaching the ... of physicians to deliver drugs directly to the brain, ... Rensselaer Polytechnic Institute are endeavoring to solve this problem ...
... Germany, several national health campaigns promote cancer screening by announcing ... is supposed to motivate men to have an examination. But ... journal of the Association for Psychological Science, finds that this ... less likely to choose to get screened. In ...
... Reinberg HealthDay Reporter , MONDAY, July 26 ... cancers, those whose level of prostate-specific antigen (PSA) is ... new study shows. Recent evidence has shown that ... the cancer they die from, but another condition. For ...
Cached Medicine News:Health News:Reform of primary care could reduce diagnostic errors 2Health News:Reform of primary care could reduce diagnostic errors 3Health News:Reform of primary care could reduce diagnostic errors 4Health News:NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer 2Health News:Smaller hospitals can provide safe and high-quality surgical care comparable to larger counterparts 2Health News:Smaller hospitals can provide safe and high-quality surgical care comparable to larger counterparts 3Health News:Breaching the blood-brain barrier to create powerful new tools for fighting cancer 2Health News:Breaching the blood-brain barrier to create powerful new tools for fighting cancer 3Health News:Few people are doing it, so why should I? Motivating men to seek cancer screening 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 3
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
Lumenis 950 Slit Lamp Zeiss-style diagnostic slit lamp biomicroscope with parallel optics and offering a choice of automatic or fixed eye safety filters for multiple wavelengths....
... Nd:YAG Base Platform is an ... the anterior segment of the ... of secondary cataracts and performing ... offers multiple upgrade options that ...
... Catheter Delivery System (CDS) facilitates ... of the Aescula LV Left-Heart ... a patented coronary sinus curve ... easy access to the coronary ...
Medicine Products: